586,446,546 Searches 3,372,377 Submissions 862,790 Sites 4,907 Featured 1,083 Categories 322,495 Editors
The fixed dose combination (FDC) of netupitant and palonosetron market is a product proposed for the treatment of the most common side effects of chemotherapy-nausea and vomiting. The product is currently in its third stage of trial. Netupitant is a novel and a NK1 receptor antagonist, and palonosetron is a second-generation 5-HT3 receptor antagonist.
Text Only Listing Upgrade
71 views, Last viewed on Thursday, April 25th, 2024 at 4:19am
Submitted by Peter
Text Only Listing Upgrade
Comments (0)
Rate This
0 Like This Like It!
Featured Articles
Free eGift Card Giveaways for Birthdays, Prime Day, St Patrick's Day, and many more.